

# UCSF

## UC San Francisco Previously Published Works

### Title

Amino acid residues 24-31 but not palmitoylation of cysteines 30 and 45 are required for membrane anchoring of glutamic acid decarboxylase, GAD65.

### Permalink

<https://escholarship.org/uc/item/7pq9s0c3>

### Journal

The Journal of cell biology, 124(6)

### ISSN

0021-9525

### Authors

Shi, Y  
Veit, B  
Baekkeskov, S

### Publication Date

1994-03-01

### DOI

10.1083/jcb.124.6.927

Peer reviewed

# Amino Acid Residues 24–31 but not Palmitoylation of Cysteines 30 and 45 Are Required for Membrane Anchoring of Glutamic Acid Decarboxylase, GAD<sub>65</sub>

Yuguang Shi, Barbara Veit, and Steinunn Bækkeskov

Departments of Medicine, and Microbiology and Immunology, and Hormone Research Institute, University of California, San Francisco, California 94143-0534

**Abstract.** The smaller isoform of the GABA synthesizing enzyme glutamic acid decarboxylase, GAD<sub>65</sub>, is synthesized as a soluble protein that undergoes post-translational modification(s) in the NH<sub>2</sub>-terminal region to become anchored to the membrane of small synaptic-like microvesicles in pancreatic  $\beta$  cells, and synaptic vesicles in GABA-ergic neurons. A soluble hydrophilic form, a soluble hydrophobic form, and a hydrophobic firmly membrane-anchored form have been detected in  $\beta$  cells. A reversible and hydroxylamine sensitive palmitoylation has been shown to distinguish the firmly membrane-anchored form from the soluble yet hydrophobic form, suggesting that palmitoylation of cysteines in the NH<sub>2</sub>-terminal region is involved in membrane anchoring. In this study we use site-directed mutagenesis to identify the first two

cysteines in the NH<sub>2</sub>-terminal region, Cys 30 and Cys 45, as the sites of palmitoylation of the GAD<sub>65</sub> molecule. Mutation of Cys 30 and Cys 45 to Ala results in a loss of palmitoylation but does not significantly alter membrane association of GAD<sub>65</sub> in COS-7 cells. Deletion of the first 23 amino acids at the NH<sub>2</sub> terminus of the GAD<sub>65</sub>/45A mutant also does not affect the hydrophobicity and membrane anchoring of the GAD<sub>65</sub> protein. However, deletion of an additional eight amino acids at the NH<sub>2</sub> terminus results in a protein which is hydrophilic and cytosolic. The results suggest that amino acids 24–31 are required for hydrophobic modification and/or targeting of GAD<sub>65</sub> to membrane compartments, whereas palmitoylation of Cys 30 and Cys 45 may rather serve to orient or fold the protein at synaptic vesicle membranes.

**F**LEXIBLE membrane association is an important feature of several proteins involved in membrane trafficking and intracellular signaling (Fischer et al., 1990; Magee et al., 1987; Pate Skene and Virág, 1989; Levis and Bourne, 1992). It is also a characteristic of some enzymes involved in the biosynthesis of neurotransmitters. Thus glutamic acid decarboxylase, the smaller form of the  $\gamma$ -amino butyric acid (GABA) synthesizing enzyme glutamic acid decarboxylase, GAD<sub>65</sub>,<sup>1</sup> (Christgau et al., 1991, 1992), tyrosine hydroxylase, the initial and rate limiting enzyme in the synthesis of catecholamines (Kuhn et al., 1990), and dopamine  $\beta$ -hydroxylase, the final enzyme in the synthesis of norepinephrine (Bon et al., 1991), share flexible membrane anchoring to secretory vesicles that store and release their neurotransmitter, suggesting an important regulatory role of membrane localization.

Address all correspondence to S. Bækkeskov, Hormone Research Institute, University of California, San Francisco, 513 Parnassus Avenue, Room HSW 1090, San Francisco, CA, 94143-0534.

1. *Abbreviations used in this paper:* aa, amino acid; GABA,  $\gamma$ -amino butyric acid; GAD, glutamic acid decarboxylase; MHC, major histocompatibility complex; PLP, pyridoxal 5'-phosphate; wt, wild-type.

GAD is encoded for by two distinct non-allelic genes, GAD<sub>67</sub> and GAD<sub>65</sub>, which are probably derived from a common ancestor gene and share significant homology except in the first 95 amino acids (Erlander et al., 1991). Both proteins are synthesized in the cytoplasm as hydrophilic and soluble molecules, and GAD<sub>67</sub> remains in this form. GAD<sub>65</sub> is posttranslationally modified and becomes anchored to the membrane of small synaptic-like microvesicles (Christgau et al., 1991, 1992). The two GAD proteins appear to comprise a dual system for GABA synthesis (Erlander et al., 1991). GAD<sub>67</sub> is tightly associated with the coenzyme pyridoxal 5'-phosphate (PLP), and may be responsible for constitutive production of GABA. A significant fraction of GAD<sub>65</sub> is detected as the apoenzyme and is PLP inducible. Thus activation of GAD<sub>65</sub> can be regulated by PLP levels, and this form may be responsible for generation of GABA in situations of sudden increases in GABA demand (Martin et al., 1991). The membrane localization of GAD<sub>65</sub> may facilitate delivery of GABA directly to a synaptic vesicle or synaptic like microvesicle for rapid accumulation and secretion. In contrast GABA synthesized by GAD<sub>67</sub>, if destined for regulatory secretion, has to be transported from the cytosol and taken up by synaptic vesicles.

The GAD<sub>65</sub> protein is unusually susceptible to becoming a target of autoimmunity that affects its major sites of expression, pancreatic  $\beta$  cells and GABA-ergic neurons. Thus GAD<sub>65</sub> is a major target antigen in both Type 1 diabetes, which results from an autoimmune destruction of  $\beta$  cells (Bækkeskov et al., 1990; Tisch et al., 1993; Kaufman et al., 1993), and in stiff-man syndrome which affects GABA-ergic neurons (Solimena et al., 1990). In contrast, GAD<sub>67</sub> does not seem to play an independent role as an autoantigen. Rather, GAD<sub>67</sub> appears to be recognized only when the immune response to GAD<sub>65</sub> involves cross-reacting epitopes in the two proteins (Velloso et al., 1993; Hagopian et al., 1993; Seibler et al., 1993). We have proposed that the membrane anchoring of GAD<sub>65</sub> to a secretory vesicle is of significance for the presentation of this form to the immune system and its selective role as an autoantigen (Christgau et al., 1992).

The posttranslational membrane anchoring of GAD<sub>65</sub> involves at least two steps. The first step is irreversible and results in a hydrophobic molecule which is still mainly localized in the cytosol. The second step is reversible and results in a firm membrane anchoring of the protein (Christgau et al., 1991). The soluble and membrane associated forms of GAD<sub>65</sub> show identical location on two-dimensional gels, suggesting that they are distinguished by small noncharged lipid moieties (Christgau et al., 1991). The modifications of GAD<sub>65</sub> do not seem to involve polyisoprenylation, myristoylation, or a phosphatidylinositol glycan. However, palmitoylation distinguishes the membrane-associated and soluble forms of GAD<sub>65</sub>, suggesting that this fatty acid is involved in membrane anchoring (Christgau et al., 1992). GAD<sub>65</sub> has a proteolytic hot spot 69–80 amino acids into the molecule. Trypsin cleavage at amino acid (aa) 69 or 70 results in a soluble hydrophilic COOH-terminal fragment and a small membrane bound palmitoylated fragment, demonstrating that the NH<sub>2</sub>-terminal region is the site of lipid modification and membrane anchoring of GAD<sub>65</sub> (Christgau et al., 1992). Consistent with this result, a hybrid molecule containing the NH<sub>2</sub>-terminal 1–83 amino acids of the GAD<sub>65</sub> molecule and amino acids 89–593 from GAD<sub>67</sub> is membrane associated (Solimena et al., 1993).

In this study we have analyzed the structural requirements of palmitoylation of GAD<sub>65</sub> and assessed its role in membrane anchoring. Our results suggest that palmitoylation does not play the major role in membrane anchoring of GAD<sub>65</sub>. Rather a small segment of amino acids adjacent to the palmitoylation sites is required for targeting and membrane anchoring of GAD<sub>65</sub>.

## Materials and Methods

### Generation of GAD<sub>65</sub> Mutants

A 2.4-kb cDNA clone of rat GAD<sub>65</sub> (a gift from Dr. A. Tobin, University of California, Los Angeles, CA) was used in this study (Erlander and Tobin, 1991). The cDNA carried the entire coding region and 80- and 400-bp 5' and 3' untranslated sequences, respectively, and was originally cloned into the EcoRI site of the Bluescript vector (Stratagene, La Jolla, CA). The sequence spanning the first AUG was altered to match the Kozak consensus sequence for optimum translation efficiency (Kozak, 1991) by site directed in vitro mutagenesis. The resulting plasmid was named pBL-YS10. Oligonucleotide-mediated in vitro mutagenesis was carried out according to Kunkel (1987). Sequencing of mutant DNA with Sequenase (Boehringer Mannheim Corp., Indianapolis, IN) was carried out using protocols

provided by the manufacturer. The wild-type cDNA with a Kozak sequence was subcloned from pBL-YS10 into the KpnI and NotI sites of the expression vector pSV-SPORT (GIBCO BRL, Gaithersburg, MD). The resulting plasmid was named pSV-YS10 (see Fig. 2, WT). Amino acid substitution mutants were generated by changing Cys to Ala or Ser residues using pBL-YS10 as template DNA. The resulting mutant DNAs were subcloned into the NotI and HindIII sites of the pCDM8 vector (Seed and Aruffo, 1987) or KpnI and XbaI sites of the pSV-SPORT vector. Expression vectors that carry Cys to Ala substitutions were pCDM-YS17 (see Fig. 2 A, Cys 30 to Ala, 30A), pCDM-YS35 (see Fig. 2 A, Cys 45 to Ala, 45A), and pSVYS17/35 (see Fig. 2 A, Cys 30 and Cys 45 to Ala, 30/45A). The expression vectors that carry Cys to Ser substitutions were pCDM-YS1 (see Fig. 2 A, Cys 73 to Ser, 73S), pCDM-YS2 (see Fig. 2 A, Cys 75 to Ser, 75S), pCDM-YS3 (see Fig. 2 A, Cys 73 and Cys 75 to Ser, 73/75S), pCDM-YS4 (see Fig. 2 A, Cys 80 to Ser, 80S), pCDM-YS5 (see Fig. 2 A, Cys 82 to Ser, 82S), pCDM-YS6 (see Fig. 2 A, Cys 80 and Cys 82 to Ser, 80/82S), pCDM-YS39 (see Fig. 2 A, Cys 75, Cys 80, and Cys 82 to Ser, 75/80/82S), and pCDM-YS8 (see Fig. 2 A, Cys 101 to Ser, 101S). Plasmid pMT-YS11 carried an insertion of a cDNA fragment lacking the NH<sub>2</sub>-terminal 101 amino acids at the EcoRI site of the expression vector pMT2 (a kind gift from R. J. Kaufman, Genetics Institute, Cambridge, MA). The deletion fragment was generated by oligonucleotide-directed mutagenesis by changing the Cys 101 into the first AUG codon flanked by a Kozak consensus sequence (Kozak, 1991) and an EcoRI site 5' to the consensus sequence.

Expression plasmids for wild-type and mutant p21<sup>H-ras</sup> (181/4S) were kindly donated by Dr. J. Hancock (Onyx, Emeryville, CA) (Hancock et al., 1990).

### Generation of Deletion Mutants by PCR

Systematic deletions of the amino terminus of the rat GAD<sub>65</sub> 30/45A mutant were generated by polymerase chain reactions (PCRs) using anchored primers. The 5' primers carried an overhang containing the Kozak consensus sequence (Kozak, 1991), and the 3' primers carried an overhang containing a translation termination codon. The 5' and 3' primer also carried a KpnI site upstream from the Kozak consensus sequence and an XbaI site downstream of the termination codon to facilitate unidirectional insertion of the amplified expression cassette into the KpnI and XbaI sites of the COS expression vector pSV-SPORT. Plasmid pCDM-YS17/35 was used as template DNA. The high fidelity Pfu thermostable DNA polymerase (Stratagene) was used to minimize the rate of mismatches in the amplification reaction.

Sequencing of the deletion mutants was carried out with an automated sequencing apparatus (Applied Biosystems, Inc., Foster City, CA). The deletion fragments were subcloned into the KpnI and BglII sites of the expression vector pSV-YS10 replacing the first 357 amino acids of GAD<sub>65</sub> with a deleted NH<sub>2</sub>-terminal region. Expression vectors that carry the NH<sub>2</sub>-terminal deletions were pSV-YS63,  $\Delta$ 1-8; pSV-YS64,  $\Delta$ 1-15; pSV-YS65,  $\Delta$ 1-23; pSV-YS66,  $\Delta$ 1-31; pSV-YS67,  $\Delta$ 1-38 (Fig. 2 B).

### Culture of Cells and Transfection

For transient transfection, COS-7 cells were seeded on 60-mm petri dishes and cultured for 15–24 h to 60–70% confluency. The cells were transfected using DOTAP (Boehringer Mannheim Corp.) by adding 100  $\mu$ l mixture containing 5  $\mu$ g DNA and 25  $\mu$ l DOTAP in transfection buffer (20 mM Hepes/NaOH, pH 7.4, 150 mM NaCl). Transfected cells were refreshed after 12–18 h and incubated for additional 48 h before biosynthetic labeling and immunoprecipitation studies or harvesting for subcellular fractionation and/or Triton X-114 partition studies.

### Antisera

The antisera used in this study included two rabbit polyclonal antisera, 1266 and 1267, and two mouse monoclonal antibodies, GAD6 and Ab-1. The 1266 and 1267 antisera (a gift from J. S. Petersen, Hagedorn Research Laboratory, Gentofte, Denmark) and the 1701 serum were raised in rabbits against a synthetic peptide containing the last 19 amino acids of the COOH-terminal region of GAD<sub>67</sub>. These antisera recognize GAD<sub>65</sub> and GAD<sub>67</sub> equally well on western blots (Kim et al., 1993). The GAD6 monoclonal antibody (Chang and Gottlieb, 1988) (a gift from Dr. D. Gottlieb, Washington University, St. Louis, MO) is specific for GAD<sub>65</sub> (Kim et al., 1993). Monoclonal antibody Ab-1 against p21<sup>H-ras</sup> was from Oncogene Science Inc. (Uniondale, NY).

## Biosynthetic Labeling and Immunoprecipitation

For labeling with [ $^{35}$ S]methionine, cells were washed twice in methionine free DME medium and incubated for 4 h in 2.5 ml of the same medium supplemented with 100  $\mu$ Ci [ $^{35}$ S]methionine, 1% fetal calf serum, 100 U/ml penicillin, and 100  $\mu$ g/ml streptomycin. For labeling with [ $^3$ H]palmitic acid, cells ( $10^6$  in a 60-mm petri dish) were washed twice in DME, followed by incubation for 4 h in 2.5 ml of DME supplemented with 0.5 mCi [ $^3$ H]palmitic acid, 1% fetal calf serum, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 2 mM glutamine, nonessential amino acids (50  $\mu$ M alanine, 100  $\mu$ M each of asparagine, aspartic acid, glutamic acid, glycine, proline, and serine), and 5 mg/ml fatty acid free bovine serum albumin. After labeling, cells were washed once in ice cold DME, then twice in cell harvesting buffer (20 mM Hepes/NaOH, pH 7.4, 150 mM NaCl, 10 mM benzamidine/HCl). Washed cells were extracted in 0.5 ml hypotonic Hepes buffer (10 mM Hepes/NaOH, pH 7.4, 1 mM  $MgCl_2$ , 1 mM aminocaprylate, 1 mM ethylenediamine, 0.2 mM PLP, 1 mM PMSF containing 1% Triton X-114), followed by centrifugation to remove insoluble debris. The soluble extracts (500  $\mu$ l) were subjected to immunoprecipitation analysis. Immunoprecipitation of labeled GAD $_{65}$  proteins was performed as described previously by Christgau et al., (1991, 1992) using the monoclonal antibody GAD6 for GAD $_{65}$  and its point mutants, and antiserum 1266 for deletion mutant pMT-Y511. Before immunoprecipitation with the 1266 antiserum, the cell extract was supplemented with 0.1% SDS. Immunoprecipitates were analyzed by 10% SDS-PAGE and fluorography (Bækkeskov et al., 1989).

## Subcellular Fractionation

Transfected COS 7 cells from a 6-cm petri dish ( $10^6$ ) were washed twice with phosphate buffered saline and homogenized at 4°C in 0.5 ml of hypotonic Hepes buffer containing 1 mM  $Na_3VO_4$ . The homogenate was centrifuged at 800 g for 10 min at 4°C to pellet the nuclei. The postnuclear supernatant was centrifuged at 100,000 g for 1 h to separate cytosol (S) and particulate fractions. The resulting pellet was resuspended and incubated for 1 h at room temperature with membrane washing buffer (10 mM Hepes/NaOH, pH 7.4, 0.5 M NaCl, 0.1 mM *p*-chloromercuriphenyl sulfonic acid, 5 mM EDTA, 0.25% trasyol, 5 mM NaF, 10 mM benzamidine/HCl, 0.1 mM  $Na_3VO_4$ , 0.2 mM PLP, 3 mM PMSF), followed by ultracentrifugation at 100,000 g for 1 h to pellet the washed membranes. Washed membranes were extracted for 2 h at 4°C with hypotonic Hepes buffer containing 1% Triton X-114 followed by centrifugation for 45 min at 100,000 g to separate the particulate extract (P) from insoluble debris. The cytosol proteins and proteins extracted from washed membranes were subjected to Triton X-114 partition assays.

Triton X-114 partitioning assays were performed on the subcellular fractions described above or on Triton X-114 detergent extracts of total cells, using a modification of the procedure of Bordier (1981). For comparative analyses of the amphiphilic properties of GAD $_{65}$  in subcellular fractions, buffer compositions were adjusted to achieve identical conditions in each fraction. Triton X-114 phase transition of each fraction was induced by incubation at 37°C for 2 min. Aqueous (A) and detergent (D) phases were separated by centrifugation at 12,000 g for 2 min. The detergent and aqueous phases were analyzed by 10% SDS-PAGE followed by immunoblotting according to Christgau et al. (1991, 1992) using antiserum 1266 or 1267 (dilution 1:1,000) for GAD $_{65}$  and its mutant proteins and Ab-1 (dilution 1:500) for p21<sup>H-ras</sup> and its mutant proteins.

## Immunofluorescence Analyses

COS cells seeded in cover slips were cultured to 60–70% confluency before transfection with a GAD $_{65}$  expression construct or a control plasmid. 20 h later the cells were processed for immunofluorescence analysis. Each manipulation was preceded by washing of cells three times in PBS. Cells were fixed in methanol for 5 min at –20°C, before incubation in blocking buffer (PBS, 2.5% fetal bovine serum, 0.02% azide) for 10 min at room temperature. The cells were incubated with the 1701 antiserum (diluted 1:500 in blocking buffer) for 30 min at room temperature followed by incubation with a secondary antibody (rhodamine conjugated goat anti-rabbit antiserum; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) diluted 1:100 in blocking buffer. After the final wash, the cover slips were inverted onto slides with mounting medium (1 mg/ml phenylenediamine in 10 mM Tris-HCl pH 8.5, 90% glycerol), sealed with nail polish, and observed through a Zeiss Axiophot microscope (Carl Zeiss, Inc., Thornwood, NY).


## Results

### Palmitoylation and Membrane Anchoring Are Intrinsic Properties of the NH $_2$ -terminal Region of GAD $_{65}$


Analyses of trypsin fragments of GAD $_{65}$  have suggested that palmitoylation and membrane anchoring reside in a small NH $_2$ -terminal fragment of GAD $_{65}$  (Christgau et al., 1992). To confirm this finding, a NH $_2$ -terminal deletion mutant of GAD $_{65}$ , lacking the first 101 amino acids (GAD $_{65}\Delta$ 1-101), was generated and analyzed for its palmitoylation and membrane anchoring properties by transient expression in COS-7 cells. Wild-type (wt) GAD $_{65}$  incorporates [ $^3$ H]palmitic acid in COS-7 cells (Fig. 1, lane 1) and becomes membrane anchored. In contrast the GAD $_{65}\Delta$ 1-101 mutant is not palmitoylated (Fig. 1, compare lanes 5 and 10). Furthermore, immunoblotting analysis of soluble and particulate fractions isolated from transfected COS-7 cells detected the GAD $_{65}\Delta$ 1-101 protein exclusively in soluble fractions (results not shown). Those results provide strong evidence that palmitoylation and membrane anchoring is mediated by the NH $_2$ -terminal 101 amino acids of GAD $_{65}$ .

### Site-directed Mutagenesis of Cys 30 and Cys 45 Abolishes Palmitoylation of the GAD $_{65}$ Molecule

The palmitoylation in the NH $_2$ -terminal domain of GAD $_{65}$  is hydroxylamine sensitive suggesting a thioester linkage (Christgau et al., 1992). To localize the site(s) of palmitoyla-



**Figure 1.** Site-directed mutagenesis of Cys 30 and Cys 45 abolishes palmitoylation in GAD $_{65}$ . SDS-PAGE of wt GAD $_{65}$  and mutant proteins labeled with [ $^3$ H]palmitic acid or [ $^{35}$ S]methionine. COS-7 cells transiently expressing wt GAD $_{65}$ , or the 30A, 45A,  $\Delta$ 1-101, and 30/45A mutant proteins were labeled with either [ $^3$ H]palmitic acid (lanes 1–5) or [ $^{35}$ S]methionine (lanes 6–10) and immunoprecipitated with either the GAD6 antibody (lanes 1–4 and 6–9) or the 1266 antiserum (lanes 5 and 10). 30A: replacement of Cys 30 with Ala; 45A: replacement of Cys 45 with Ala;  $\Delta$ 1-101: deletion of the NH $_2$ -terminal 101 amino acids; 30/45A: replacement of both Cys 30 and Cys 45 with Ala. To obtain similar intensity of radioactive proteins on fluorograms, the ratio between immunoprecipitated [ $^{35}$ S]methionine and [ $^3$ H]palmitic acid-labeled proteins subjected to SDS-PAGE was 1:40.




**Figure 2.** Sequence of Cys substitution mutants and NH<sub>2</sub>-terminal deletion mutants of GAD<sub>65</sub>. (A) Mutations of cysteine residues in the NH<sub>2</sub>-terminal region of GAD<sub>65</sub>. The wt GAD<sub>65</sub> sequence is given at the top with the positions of the cysteines to be mutated given in bold face. The substitutions for these cysteines are indicated for each mutant. The dashed lines denote amino acids which are identical in wt and mutant proteins. (B) NH<sub>2</sub>-terminal deletions of the GAD<sub>65</sub>30/45A mutant. The wild-type sequence is indicated at the top. The dashed lines indicate amino acids which are identical in wt and mutant protein. None of the deletion mutants carry the palmitoylation sites (Cys 30 and Cys 45). An additional substitution of Phe to Val was introduced into the Δ1-8 deletion mutant to generate a Kozak DNA consensus sequence for translation efficiency (Kozak 1991).

tion and to investigate the role of this fatty acid in membrane anchoring, cysteine residues in the NH<sub>2</sub>-terminal region were systematically substituted by alanine or serine residues using site directed in vitro mutagenesis (Fig. 2 A). The substitution mutants were transiently expressed in COS-cells and analyzed for incorporation of [<sup>3</sup>H]palmitic acid in biosynthetic labeling experiments. All of the single cysteine substitution mutants incorporated [<sup>3</sup>H]palmitic acid (not shown). Analyses of a series of mutants containing substitutions of combinations of two and three cysteines in the NH<sub>2</sub>-terminal region (Fig. 2 A) identified one mutant that had lost the ability to incorporate [<sup>3</sup>H]palmitic acid (Fig. 1, lane 4). All the other combinations of double and triple cysteine mutations shown in Fig. 2 A incorporated palmitic acid (not shown). In the non-palmitoylated mutant (30/45A) Cys 30 and Cys 45 were replaced by alanine. The result suggests that Cys 30 and Cys 45 are the sites of posttranslational palmitoylation in GAD<sub>65</sub>.

#### Non-palmitoylated Form of GAD<sub>65</sub> Remains Hydrophobic and Membrane Bound in COS-7 Cells

To investigate the effect of loss of palmitoylation on the hydrophobicity of GAD<sub>65</sub>, Triton X-114 extracts of COS-7 cells expressing either wt GAD<sub>65</sub> or the 30/45A mutant were subjected to temperature induced Triton X-114 phase transition. The detergent and aqueous phases were separated




**Figure 3.** Partition of GAD<sub>65</sub>, GAD<sub>65</sub>30/45A and deletion mutants of GAD<sub>65</sub>30/45A into Triton X-114 detergent phase. Triton X-114 total cell extracts of COS-7 cells expressing the indicated mutants were subjected to temperature induced phase separation and the aqueous (A) and detergent (D) phases analyzed by SDS-PAGE and immunoblotting using the 1267 antiserum, which recognizes the COOH terminus of GAD.

and analyzed by immunoblotting (Fig. 3). These analyses showed that the 30/45A mutant partitioned into the Triton X-114 detergent phase at a similar ratio as the wt protein (Fig. 3, compare lanes 1 and 2 with lanes 13 and 14) demonstrating that the non-palmitoylated 30/45A mutant is still amphiphilic. This result is consistent with the finding that palmitoylation is not the first step in the posttranslational hydrophobic modification of GAD<sub>65</sub>, but rather a subsequent step that distinguishes the hydrophobic soluble form, which has undergone the first modification, from a hydrophobic membrane anchored form (Christgau et al., 1991, 1992).

To assess the role of palmitoylation in membrane anchoring of the GAD<sub>65</sub> molecule, we analyzed the subcellular distribution of wt and the non-palmitoylated GAD<sub>65</sub>30/45A mutant expressed in COS-7 cells. The distribution of GAD<sub>65</sub> in those experiments was compared with wt and a non-palmitoylated mutant of p21<sup>H-ras</sup> which were co-transfected into COS-7 cells and analyzed in parallel.

Palmitoylation of Cys 181 and Cys 184 in p21<sup>H-ras</sup> is required for membrane anchoring and mutation of these residues to serines (p21<sup>H-ras</sup>181/184S) abolishes membrane anchoring (Hancock et al., 1990). COS-7 cells co-transfected with either wt GAD<sub>65</sub> and wt p21<sup>H-ras</sup> (Fig. 4, lanes 1-4) or GAD<sub>65</sub>30/45A and p21<sup>H-ras</sup>181/184S (Fig. 4, lanes 13-16) were homogenized and separated into a cytosol and a particulate membrane fraction. The membrane fraction was washed in 0.5 M NaCl. Proteins in the cytosolic and washed membrane fractions were subjected to Triton X-114 phase separation. The distribution of wt and non-palmitoylated mutants of GAD<sub>65</sub> and p21<sup>H-ras</sup> into the detergent and aqueous phases of each fraction was analyzed by immunoblotting. The results of these analyses are shown in Fig. 4, lanes 1-4 and 13-16.

p21<sup>H-ras</sup> is synthesized as a hydrophilic soluble molecule (Fig. 4, lanes 1 and 13) and undergoes a two step posttranslational modification at its carboxyl terminus to become membrane anchored. The first step involves farnesylation of Cys



**Figure 4.** Subcellular distribution of GAD<sub>65</sub>, GAD<sub>65</sub>30/45A, and deletion mutants of GAD<sub>65</sub>30/45A in COS-7 cells. A cytosolic fraction (S) and an extract of a washed membrane fraction (P) were prepared from COS-7 cells expressing the indicated proteins and subjected to Triton X-114 phase separation. Wild-type p21<sup>H-ras</sup> was co-expressed with wt GAD<sub>65</sub> (lanes 1–4) and the GAD<sub>65</sub>30/45AΔ1–31 mutant (lanes 5–8). The non-palmitoylated ras mutant 181/184S was co-expressed with the GAD<sub>65</sub>30/45AΔ1–38 (lanes 9–12) and GAD<sub>65</sub>30/45A (lanes 13–16). Aqueous (A) and detergent (D) phases were analyzed by SDS-PAGE and immunoblotting with the antiserum 1267 for GAD<sub>65</sub> and its mutants and antiserum Ab-1 for p21<sup>H-ras</sup> and its mutants. Arrows indicate the position of the GAD and ras proteins. The wild-type ras is detected as an immature cytosolic form present only in the aqueous phases (lanes 1 and 5) and as the fully modified farnesylated and palmitoylated membrane anchored form detected exclusively in the detergent phase (lanes 4 and 8). In the 181/184S mutant of ras, the palmitoylation sites (Cys 181 and Cys 184) are mutated to serine. Lack of palmitoylation abolishes membrane anchoring and hence this mutant accumulates as the immature hydrophilic and cytosolic form (lanes 9 and 13) and as a farnesylated, hydrophobic but soluble form (lanes 10 and 14). In contrast, lack of palmitoylation of the GAD<sub>65</sub> protein does not result in a significant change in membrane anchoring or distribution between aqueous and detergent phases (compare lanes 1–4 with lanes 13–16). However deletion of amino acids 1–31 and 1–38 in the non-palmitoylated GAD<sub>65</sub>30/45A mutant result in hydrophilic mutant proteins predominantly located in the cytosol.

186, proteolytic removal of the last three amino acids and carboxyl methylation of the Cys 186 carboxyl terminus (Hancock et al., 1989; Schafer et al., 1989; Casey et al., 1989; Gutierrez et al., 1989). The farnesylated form of ras is hydrophobic and cytosolic. The second step involves a reversible palmitoylation of Cys 181 and Cys 184 and results in a firmly membrane anchored protein (Hancock et al., 1989) (Fig. 4, lane 4). In the p21<sup>H-ras</sup>181/184S mutant membrane anchoring is abolished (Hancock et al., 1990) and the farnesylated form of p21<sup>H-ras</sup> accumulates (Fig. 4, lane 14).

In COS-7 cells, as in pancreatic  $\beta$  cells, wt GAD<sub>65</sub> protein is detected in both cytosol and membrane fractions, consistent with its presence in both soluble and membrane anchored forms (Fig. 4, lanes 1–4; Christgau et al., 1991, 1992). In both cytosolic and membrane fractions the wt GAD<sub>65</sub> protein distributes into the Triton X-114 detergent phase consistent with the hydrophobic soluble and hydropho-

bic membrane anchored forms demonstrated for this protein (Christgau et al., 1991, 1992). The hydrophobic GAD<sub>65</sub> forms, in contrast to the p21<sup>H-ras</sup> forms, never partition completely into the detergent phase but are consistently detected in both aqueous and detergent phases (Christgau et al., 1991, 1992). It is likely that the size of GAD<sub>65</sub> precludes its quantitative partitioning into the detergent phase (Bjerrum et al., 1983). The majority of the wt GAD<sub>65</sub> protein is however found together with the wt p21<sup>H-ras</sup> protein in the detergent phases of the membrane fraction (Fig. 4, lane 4). The GAD<sub>65</sub>30/45A mutant behaved similarly to the wt protein in those analyses (Fig. 4, compare lanes 1–4 with 13–16). Thus a significant fraction of the non-palmitoylated mutant protein was found in membrane fractions where it distributed into the Triton X-114 detergent phase (Fig. 4, lane 16). In comparison, the p21<sup>H-ras</sup>181/184S mutant was found exclusively in the cytosol fraction. Thus in contrast to p21<sup>H-ras</sup>, palmitoylation of the GAD<sub>65</sub> protein is not a requirement for membrane anchoring. Instead other modification(s) in the NH<sub>2</sub>-terminal region are implied. Those results motivated an investigation of which part of the NH<sub>2</sub>-terminal region is required for hydrophobic modification of membrane anchoring of GAD<sub>65</sub>.

### Amino Acid Residues 24–31 Are Essential for Membrane Anchoring of GAD<sub>65</sub>

To further localize the sequences in the NH<sub>2</sub>-terminal region which are required for targeting and anchoring of GAD<sub>65</sub> to membrane compartments, we analyzed the effect of stepwise deletions of NH<sub>2</sub>-terminal sequences in the GAD<sub>65</sub>30/45A mutant on the hydrophobicity and membrane anchoring of the resulting proteins (Fig. 2 B). The mutants were transiently expressed in COS-7 cells and analyzed in Triton X-114 partition assays (Fig. 3), in parallel with wt GAD<sub>65</sub> and the 30/45A mutant from which they were derived. Deletions of up to 23 NH<sub>2</sub>-terminal amino acids of the 30/45A mutant did not result in significant changes in hydrophobicity of the resulting proteins (Fig. 3, compare lanes 3–8 with lanes 1–2). However, deletion of an additional eight amino acids (Δ1–31) resulted in a protein which did not partition into the Triton X-114 detergent suggesting that this protein does not undergo hydrophobic modifications and hence remains hydrophilic. This mutant protein was expressed at lower levels than the shorter deletion mutants (Figs. 3 and 4) suggesting that it is less stable than the other mutants. However deletion of an additional seven amino acids (Δ1–38) resulted in a protein which was expressed at similar levels as the shorter deletion mutants. The Δ1–38 mutant also did not partition into the Triton X-114 detergent phase demonstrating that it does not undergo hydrophobic modification and therefore remains hydrophilic (Fig. 3). Analyses of subcellular distribution of the deletion mutants in COS-7 cells confirmed that both the Δ1–31 and Δ1–38 mutants were hydrophilic and predominantly localized in the cytosol fraction (Fig. 4, lanes 5 and 9). In conditions (wash of membrane fraction in 0.5 M NaCl) where all of the non-palmitoylated but farnesylated p21<sup>H-ras</sup> 181/184S protein was localized in the cytosolic fraction (Fig. 4, lane 10), a small fraction of the non-palmitoylated and hydrophilic Δ1–31 and Δ1–38 GAD<sub>65</sub> was detected in the aqueous phase of the membrane fraction (Fig. 4, lanes 7 and 11). Thus it appears

that the  $\Delta$ 1-31 and  $\Delta$ 1-38 deletion mutants maintain a low level of membrane avidity in the absence of posttranslational hydrophobic modification(s) perhaps by association with a membrane protein. These data show that deletion of amino acids 24–31 in the non-palmitoylated GAD<sub>65</sub> mutant results in a loss of hydrophobic modification and a predominant localization in the cytosol. Thus amino acids 24–31 are required for hydrophobic modification and appropriate membrane anchoring of GAD<sub>65</sub>.


### Immunofluorescence Analyses of Wild Type and Mutants of GAD<sub>65</sub> in COS-7 Cells

GAD<sub>65</sub> is anchored to the membrane of synaptic-like microvesicles in pancreatic  $\beta$  cells (Christgau et al., 1992), but remains associated with the Golgi apparatus in transfected CHO cells (Solimena et al., 1993). We analyzed the subcellular distribution of wt GAD<sub>65</sub>, the 30/45A mutant, and the  $\Delta$ 1-38 mutant in COS-7 cells by indirect immunofluorescence. In COS-7 cells wt GAD<sub>65</sub> is localized in a large membranous perinuclear compartment, and in punctate like structures that may represent membrane vesicles (Fig. 5 a). No significant difference was observed between the wt protein and the 30/45A mutant (not shown). The  $\Delta$ 1-38 mutant was evenly distributed in a diffuse pattern throughout the cytosol (Fig. 5 b), which is similar to the cellular distribution of GAD<sub>67</sub> (Solimena et al., 1993; and our unpublished results). The immunofluorescence analyses of the cellular distribution of wt GAD<sub>65</sub> and the two mutants are consistent with the results from subcellular analyses and confirm that the  $\Delta$ 1-38 deletion mutant is predominantly cytosolic in contrast to the wt protein which is associated with membrane compartments.

### Discussion

The NH<sub>2</sub>-terminal region distinguishes the two isoforms of mammalian glutamate decarboxylase, GAD<sub>65</sub> and GAD<sub>67</sub>, and is altogether absent in *Drosophila* GAD (Erlander et al., 1991). It is possible that this region has evolved to target the two mammalian enzymes to different sub-cellular compartments. Thus, while the GAD<sub>67</sub> protein is localized in the cytosolic compartment, the NH<sub>2</sub>-terminal region of GAD<sub>65</sub> mediates targeting and anchoring to membranous compartments in both endocrine (Christgau et al., 1992) and non-endocrine cells (Christgau et al., 1992; Solimena et al., 1993).

Pulse-chase analyses of GAD<sub>65</sub> in pancreatic  $\beta$  cells suggest that the newly synthesized hydrophilic enzyme is first modified to become a hydrophobic molecule which is cytosolic or of a low membrane avidity. This form then undergoes a second set of modifications that include a hydroxylamine sensitive palmitoylation in the NH<sub>2</sub>-terminal region. These modifications result in a firmly membrane-anchored molecule which remains membrane anchored in conditions that release peripheral membrane proteins (Christgau et al., 1991). Because palmitoylation is a distinct property of the membrane anchored form (Christgau et al., 1992) we previously proposed that palmitoylation might be important for membrane anchoring of GAD<sub>65</sub>. Palmitoylation is clearly required for membrane association of some of the ras proteins, where mutation of palmitoylated cysteines results in loss of membrane anchoring (Hancock et al., 1990). In this



**Figure 5.** Immunofluorescence analyses of COS-7 cells expressing GAD<sub>65</sub> and the deletion mutant GAD<sub>65</sub>30/45A $\Delta$ 1-38. COS cells transfected with wt GAD<sub>65</sub> (a) and GAD<sub>65</sub>30/45A $\Delta$ 1-38 (b) cDNAs were immunostained with antiserum 1701 followed by visualization using a fluorescence conjugated goat anti-rabbit antiserum. The wt GAD<sub>65</sub> is concentrated in a perinuclear compartment and in small punctate like structures (vesicles) in the cytoplasm. The non-palmitoylated deletion mutant of GAD<sub>65</sub> shows diffuse cytoplasmic staining.

study we have identified Cys 30 and Cys 45 as the sites of palmitoylation in the GAD<sub>65</sub> molecule by site-directed mutagenesis. Mutation of both of these residues abolishes palmitoylation of GAD<sub>65</sub> in COS-7 cells. The non-palmitoylated mutant is still hydrophobic, which is consistent with a biosynthetic pathway in which the protein first undergoes an irreversible hydrophobic posttranslational modification(s) that results in a hydrophobic yet soluble molecule. Surprisingly, the non-palmitoylated GAD<sub>65</sub>30/45A mutant is still membrane anchored in COS-7 cells, demonstrating that palmitoylation is not essential for membrane anchoring. Our results suggest that the reversible membrane anchoring of the GAD<sub>65</sub> molecule (Christgau et al., 1992) is not mediated exclusively by a palmitoylation-depalmitoylation mechanism as it is in some of the ras proteins (Magee et al., 1987;



Hancock et al., 1989, 1990). Rather GAD<sub>65</sub> undergoes additional posttranslational modification(s) that contribute to its membrane association. The nature of this modification is currently unknown, but our previous work indicates that several lipid modifications known to contribute to membrane anchoring, including polyisoprenylation, phosphatidylinositolglypidation or myristoylation, are not involved in anchoring GAD<sub>65</sub> (Christgau et al., 1992).

Using the palmitoylation minus mutant of GAD<sub>65</sub>, we have dissected the NH<sub>2</sub>-terminal region by deleting segments of the NH<sub>2</sub> terminus and analyzing the hydrophobicity and membrane anchoring properties of the resulting mutants. The non-palmitoylated mutant lacking amino acids 1–23 was not significantly different from the wild-type protein with regard to hydrophobicity, subcellular localization and membrane anchoring. Thus the first 23 amino acids in the NH<sub>2</sub> terminus of the GAD<sub>65</sub> molecule are not required for hydrophobic modification, subcellular targeting, and membrane anchoring. However, deletion mutants which lacked an additional 8 or 15 amino acids, respectively (aa 24–31, aa 24–38) failed to undergo hydrophobic modification(s) and were predominantly localized in the cytosol. Thus it appears that amino acids 24–31 are required for both the first hydrophobic modification and the subsequent membrane anchoring of GAD<sub>65</sub>, suggesting that those events may be closely linked. It is conceivable that the first hydrophobic modification is a prerequisite for the subsequent membrane anchoring modification, as is the case for farnesylation and palmitoylation in p21<sup>H-ras</sup> and p21<sup>N-ras</sup> (Hancock et al., 1989). Alternatively, the first hydrophobic modification and the membrane anchoring moiety in GAD<sub>65</sub> may be independent but spatially linked and thus both affected by deletion of amino acids 24–31. Mass spectrometric analyses will address the question whether the amino acid 24–31 segment itself is posttranslationally modified in the wild-type protein.

It can not be excluded that deletion of amino acids 24–31 in the GAD<sub>65</sub> protein results in a conformational change elsewhere in the molecule which is incompatible with targeting and anchoring of GAD<sub>65</sub> to membrane compartments. It is more likely however that the major effect of deletion is local, which would suggest that the palmitoylated Cys 30 and Cys 45 residues are adjacent to the additional hydrophobic and membrane anchoring moieties in GAD<sub>65</sub>.

What is the role of palmitoylation in GAD<sub>65</sub>? Our results suggest that palmitoylation is not required for membrane anchoring of GAD<sub>65</sub>. One possibility is that palmitoylation presents a redundant or alternative membrane anchoring moiety in the GAD<sub>65</sub> protein perhaps analogous to the situation in the  $\alpha$  chain of several of the trimeric GTP-binding proteins, which are both palmitoylated and myristoylated (Linder et al., 1993; Parenti et al., 1993). Alternatively, it is possible that palmitoylation of GAD<sub>65</sub> adjacent to the membrane anchoring region has a different role, which is apparent in certain other membrane proteins. For example, the Vesicular Stomatitis Virus G protein (Rose et al., 1984), CD4 (Crise and Rose, 1992), the transferrin receptor (Jing and Trowbridge, 1987), and the heavy chain of the human class I histocompatibility antigen HLA-B7 (Kaufman et al., 1984; Ploegh et al., 1981) each are palmitoylated at cysteines adjacent to their membrane spanning region. In those proteins palmitoylation is not necessary for stable membrane association. Rather palmitoylation may serve a different role.

In the transferrin receptor, lack of palmitoylation increases the rate of endocytosis (Alvarez et al., 1990). In the  $\beta$ 2-adrenergic receptor, palmitoylation seems to be important for coupling to the guanyl nucleotide regulatory protein G<sub>i</sub> (Moffett et al., 1993). By analogy palmitoylation of Cys 30 and Cys 45 adjacent to the aa 23–31 segment required for membrane anchoring of GAD<sub>65</sub> may be important for modifying the orientation or folding of the protein at the membrane of synaptic vesicles or synaptic like microvesicles. Such folding may facilitate protein–protein or protein–lipid interactions and be important for the function of the enzyme.

We have shown that a 57-kD hydrophilic soluble COOH-terminal fragment of GAD<sub>65</sub> can be spontaneously released from islet cell membranes as a function of time suggesting an enzymatic reactivity that can cleave the protein downstream from the membrane anchoring region (Christgau et al., 1992). The 57-kD fragment is detected in islet cell (Christgau et al., 1991) and brain extracts (our unpublished results) suggesting that this reactivity is present in both tissues. Thus, in addition to the reversible membrane anchoring of GAD<sub>65</sub>, which may confer a flexible and perhaps regulated on–off mechanism of membrane anchoring, there may be a second and irreversible mechanism that can release the protein from membrane compartments as a fragment that has lost the membrane anchoring domain.

It is not known whether the reversible targeting of GAD<sub>65</sub> to the membrane of synaptic vesicles or synaptic-like microvesicles plays a role in its presentation to the immune system and thus its unique autoantigenicity compared with GAD<sub>67</sub>. It can be hypothesized that reversible anchoring to the membrane of synaptic vesicles which are part of the endocytic/exocytic membrane network, and perhaps also the proteolytic release mechanism described above, targets the protein for increased degradation and presentation by MHC class I antigens for recognition by cytotoxic T-cells. Alternatively, the membrane-anchored GAD<sub>65</sub> may be targeted to the surface during exocytosis for recognition by autoantibodies. Whereas the first mechanism appears relevant for T-cell-mediated destruction of pancreatic  $\beta$  cells, the second possibility may be the only mechanism by which GABAergic neurons can present the protein to the immune system in the absence of MHC class I antigen expression.

We thank Drs. John Hancock and Allan Tobin for donation of cDNAs, Drs. D. Gottlieb and J. S. Petersen for donation of antibodies, and Drs. D. Hana-han, K. Mostov, D. Morgan, and M. Namchuk for critical reading of the manuscript.

This study was supported by National Institutes of Health grant DK41822.

Received for publication 22 November 1993 and in revised form 22 December 1993.

## References

- Alvarez, E., N. Girones, and R. J. Davis. 1990. Inhibition of the receptor-mediated endocytosis of diferric transferrin is associated with the covalent modification of the transferrin receptor with palmitic acid. *J. Biol. Chem.* 265:16644–16655.
- Bækkeskov, S., G. Warnock, M. Christie, R. V. Rajotte, P. Mose-Larsen, and S. Fey. 1989. Revelation of specificity of 64K autoantibodies in IDDM sera by high resolution 2D gel electrophoresis. Unambiguous identification of 64K target antigen. *Diabetes*. 38:1133–1141.
- Bækkeskov, S., H. J. Aanstoot, S. Christgau, A. Reetz, M. Solimena, M. Cascalho, F. Folli, H. Richter-Olesen, and P. De Camilli. 1990. Identification of the 64k autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. *Nature (Lond.)*. 347:



- Bjerrum, O. J., K. P. Larsen, and M. Wilken. 1983. Some recent developments of the electroimmunochemical analysis of membrane proteins. Application of zwittergent, Triton X-114 and Western blotting technique. In *Modern Methods in Protein Chemistry*. H. Tschesche, editor. Walter de Gruyter & Co., New York. 79-124.
- Bon, S., A. Lamouroux, A. Vigny, J. Massoulie, J. Mallet, and J. P. Henry. 1991. Amphiphilic and nonamphiphilic forms of bovine and human dopamine  $\beta$ -hydroxylase. *J. Neurochem.* 57:1100-1111.
- Bordier, C. 1981. Phase separation of integral membrane proteins in Triton X-114 solution. *J. Biol. Chem.* 256:1604-1607.
- Boyd, D., and J. Beckwith. 1990. The role of charged amino acids in the localization of secreted and membrane proteins. *Cell.* 62:1031-1033.
- Casey, P. J., P. A. Soloski, C. J. Der, and J. E. Buss. 1989. p21-ras is modified by a farnesyl isoprenoid. *Proc. Natl. Acad. Sci. USA.* 86:8323-8327.
- Chang, Y.-C., and D. I. Gottlieb. 1988. Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase. *J. Neurosci.* 7:2123-2130.
- Christgau, S., H. Schierbeck, H. J. Aanstoot, L. Aagard, K. Begley, H. Kofod, K. Hejnaes, and S. Bækkeskov. 1991. Pancreatic  $\beta$ -cells express two autoantigenic forms of glutamic acid decarboxylase, a 65 kDa hydrophilic form and a 64 kDa amphiphilic form which can be both membrane-bound and soluble. *J. Biol. Chem.* 266:21257-21264.
- Christgau, S., H. J. Aanstoot, H. Schierbeck, K. Begley, S. Tullin, K. Hejnaes, and S. Bækkeskov. 1992. Membrane anchoring of the autoantigen GAD<sub>65</sub> to microvesicles in pancreatic  $\beta$ -cells by palmitoylation in the NH<sub>2</sub>-terminal domain. *J. Cell Biol.* 118:309-320.
- Crise, B., and J. K. Rose. 1992. Identification of palmitoylation sites on CD4, the human immunodeficiency virus receptor. *J. Biol. Chem.* 267:13593-13597.
- Erlander, M. G., N. J. K. Tillakaratne, S. Feldblum, N. Pate, and A. J. Tobin. 1991. Two genes encode distinct glutamate decarboxylases. *Neuron.* 7:91-100.
- Fischer, V., G. Mollard, G. A. Mignery, M. Baumert, M. S. Perin, T. J. Hanson, P. M. Burger, R. Jahn, and T. C. Südhof. 1990. rab3 is a small GTP-binding protein exclusively localized to synaptic vesicles. *Proc. Natl. Acad. Sci. USA.* 87:1988-1992.
- Gutierrez, L., A. I. Magee, C. J. Marshall, and J. F. Hancock. 1989. Post-translational processing of p21<sup>ras</sup> is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. *EMBO (Eur. Mol. Biol. Organ.) J.* 8:1093-1098.
- Hagopian, W. A., B. Michelsen, A. E. Karlson, F. Larsen, A. Moody, C. E. Grubin, R. Rowe, J. Petersen, R. McEvoy, and Å. Lernmark. 1993. Autoantibodies in IDDM primarily recognize the 65,000-M<sub>r</sub> rather than the 67,000-M<sub>r</sub> isoform of glutamic acid decarboxylase. *Diabetes.* 42:631-636.
- Hancock, J. F., A. I. Magee, J. E. Childs, and C. J. Marshall. 1989. All ras proteins are polyisoprenylated but only some are palmitoylated. *Cell.* 57:1167-1177.
- Hancock, J. F., H. Paterson, and C. J. Marshall. 1990. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21<sup>ras</sup> to the plasma membrane. *Cell.* 63:133-139.
- Jing, S. Q., and I. S. Trowbridge. 1987. Identification of the intermolecular disulfide bonds of the human transferrin receptor and its lipid-attachment site. *EMBO (Eur. Mol. Biol. Organ.) J.* 6:327-331.
- Kaufman, J. F., M. S. Krangel, and J. L. Strominger. 1984. Cysteines in the transmembrane region of major histocompatibility complex antigens are fatty acylated via thioester bonds. *J. Biol. Chem.* 259:7230-7238.
- Kaufman, D. L., M. Claire-Salzler, J. Tian, T. Forsthuber, G. S. P. Ting, P. Robinson, M. A. Atkinson, E. E. Sercarz, A. J. Tobin, and P. V. Lehmann. 1993. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. *Nature (Lond.)*. 366:69-72.
- Kim, J., W. Richter, H. J. Aanstoot, Y. Shi, Q. Fu, R. Rajotte, G. Warnock, and S. Bækkeskov. 1993. Differential expression of GAD65 and GAD67 in human, rat and mouse pancreatic islets. *Diabetes.* 42:1799-1808.
- Kozak, M. 1991. Structural Features in eukaryotic mRNAs that modulate the initiation of translation. *J. Biol. Chem.* 266:19867-19870.
- Kuhn, D. M., R. Arthur, H. Yoon, and K. Sankaran. 1990. Tyrosine hydroxylase in secretory granules from bovine adrenal medulla. *J. Biol. Chem.* 265:5780-5786.
- Kunkel, T. A., J. D. Roberts, and R. A. Zakour. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. *Methods Enzymol.* 154:367-382.
- Levis, M. J., and H. R. Bourne. 1992. Activation of the subunit of G<sub>i</sub> in intact cells alters its abundance, rate of degradation and membrane avidity. *J. Cell Biol.* 119:1297-1307.
- Linder, M. E., P. Middleton, J. R. Hepler, R. Taussig, A. G. Gilman, and S. M. Mumby. 1993. Lipid modifications of G proteins:  $\alpha$  subunits are palmitoylated. *Proc. Natl. Acad. Sci. USA.* 90:3675-3679.
- Magee, A. I., L. Gutierrez, I. A. McKay, C. J. Marshall, and A. Hall. 1987. Dynamic fatty acylation of p21<sup>ras</sup>. *EMBO (Eur. Mol. Biol. Organ.) J.* 6:3353-3357.
- Martin, D. L., S. B. Martin, S. J. Wu, and N. Espina. 1991. Regulatory properties of brain glutamate decarboxylase (GAD): the apoenzyme of GAD is present principally as the smaller of two molecular forms of GAD in brain. *J. Neurosci.* 11:2725-2731.
- Moffett, S., B. Mouillac, H. Bonin, and M. Bouvier. 1993. Altered phosphorylation and desensitization patterns of a human beta 2-adrenergic receptor lacking the palmitoylated Cys341. *EMBO (Eur. Mol. Biol. Organ.) J.* 12:349-356.
- Parenti, M., M. A. Vigano, C. M. Newman, G. Milligan, and A. I. Magee. 1993. A novel N-terminal motif for palmitoylation of G-protein alpha subunits. *Biochem. J.* 291:349-353.
- Pate Skene, J. H., and I. Virág. 1989. Posttranslation membrane attachment and dynamic fatty acylation of a neuronal growth cone protein, GAP-43. *J. Cell Biol.* 108:613-624.
- Ploegh, H. L., H. T. Orr, and J. L. Strominger. 1981. Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. *Cell.* 24:287-299.
- Rose, J. K., G. A. Adams, and C. J. Gallione. 1984. The presence of cysteine in the cytoplasmic domain of the vesicular stomatitis virus glycoprotein is required for palmitate addition. *Proc. Natl. Acad. Sci. USA.* 81:2050-2054.
- Schafer, W. R., R. Kim, R. Sterne, J. Thorner, S.-H. Kim, and J. Rine. 1989. Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans. *Science (Wash. DC)* 245:379-385.
- Seed, B., and A. Aruffo. 1987. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. *Proc. Natl. Acad. Sci. USA.* 84:3365-3369.
- Seifler, J., J. Amann, L. Mauch, H. Haubruck, S. Wolfahrt, S. Bieg, W. Richter, R. Holl, E. Heinze, W. Northemann, and W. A. Scherbaum. 1993. Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus. *J. Clin. Invest.* 92:1394-1399.
- Solimena, M., F. Folli, R. Aparisi, G. Pozza, and P. De Camilli. 1990. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. *N. Engl. J. Med.* 322:1555-1560.
- Solimena, M., D. Aggüjaro, C. Muntzel, R. Dirks, M. Butler, P. De Camilli, and A. Hayday. 1993. Association of GAD-65, but not of GAD-67, with the Golgi complex of transfected Chinese hamster ovary cells mediated by the N-terminal region. *Proc. Natl. Acad. Sci. USA.* 90:3073-3077.
- Tisch, R., X.-D. Yang, S. M. Singer, R. S. Liblau, L. Fugger, and H. O. McDevitt. 1993. Immune response to glutamic acid decarboxylase correlates with insulinitis in non-obese diabetic mice. *Nature (Lond.)*. 366:72-75.
- Velloso, L. A., O. Kämpfe, A. Hallberg, L. Christmanson, C. Betsholtz, and F. Anders Karlsson. 1993. Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in Type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. *J. Clin. Invest.* 91:2084-2090.